BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the
“Company”), a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of refractory chronic cough
(“RCC”) and other hypersensitization-related disorders, today
announced that three abstracts on BLU-5937 have been accepted for
presentation at the upcoming American Thoracic Society ("ATS") 2021
International Conference, being held on May 14-19, 2021.
Mini Symposium Presentation:
Title: Improvements in Cough Frequency Over 24 Hours with
BLU-5937, a Selective P2X3 Antagonist, in Patient Subgroups Defined
by Baseline Awake Cough Frequencies Session: Hot Takes from
Clinical Trials in Lung Disease (A006) Format: Pre-recorded
presentation and live discussion period Date: Sunday, May 16
Time: 10:00 – 11:30 a.m. EDT
Poster Presentations:
Title: Design of SOOTHE, a Phase 2b Dose Finding Study
with BLU-5937, a Selective P2X3 Antagonist, in Refractory Chronic
Cough Session: Assessment and Treatment of Cough and Chronic
Dyspnea (TP044) Format: On demand
Title: Baseline Characteristics and Burden of Disease in
Populations Defined by Cough Frequency Tiers in RELIEF, a Phase 2
Study on the Efficacy and Safety of BLU-5937 in Refractory Chronic
Cough Session: Assessment and Treatment of Cough and Chronic
Dyspnea (TP044) Format: On demand
Following the conference, the presentation materials will be
available in the “Scientific Publications” section of BELLUS
Health's website at www.bellushealth.com.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of RCC and other
hypersensitization-related disorders. The Company's product
candidate, BLU-5937, is being developed for the treatment of RCC
and chronic pruritus associated with AD.
RCC is a cough lasting more than 8 weeks despite appropriate
treatment for underlying condition(s). It is estimated that there
are approximately 9 million patients in the United States suffering
from RCC. RCC is associated with significant adverse physical,
social, and psychosocial effects on health and quality of life.
Currently, there is no specific therapy approved for RCC and
current treatment options are limited.
Chronic pruritus associated with AD is an irritating sensation
that leads to scratching and persists for longer than 6 weeks in AD
patients. It is estimated that up to 10% of adults in the United
States suffer from AD – almost all report symptoms of pruritus with
over 50% of patients attributing chronic pruritus as their most
burdensome symptom. Despite currently available treatments
targeting AD, there continues to be a lack of options targeting the
burden of pruritus in patients with AD.
Forward-Looking Statements
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute "forward-looking statements" within the
meaning of Canadian securities legislation and regulations, the
U.S. Private Securities Litigation Reform Act of 1995, as amended,
and other applicable securities laws. Forward-looking statements
are frequently, but not always, identified by words such as
“expects,” “anticipates,” “believes,” “intends,” “estimates,”
“potential,” “possible,” “projects,” “plans,” and similar
expressions. Such statements, based as they are on the current
expectations of management, inherently involve numerous important
risks, uncertainties and assumptions, known and unknown, many of
which are beyond BELLUS Health's control. Such statements include,
but are not limited to, the potential of BLU-5937 to successfully
treat chronic cough, chronic pruritus and other
hypersensitization-related disorders, BELLUS Health’s expectations
related to its preclinical studies and clinical trials, including
the design and timing of its Phase 2b clinical trial of BLU-5937 in
RCC and its Phase 2 clinical trial of BLU-5937 in chronic pruritus
associated with AD, including the timing and outcome of
interactions with regulatory agencies, the potential activity and
tolerability profile, selectivity, potency and other
characteristics of BLU-5937, including as compared to other
competitor candidates, the commercial potential of BLU-5937,
including with respect to patient population, pricing and labeling,
BELLUS Health’s financial position, and the potential applicability
of BLU-5937 and BELLUS Health’s P2X3 platform to treat other
disorders. Risk factors that may affect BELLUS Health’s future
results include but are not limited to: the benefits and impact on
label of its enrichment strategy, estimates and projections
regarding the size and opportunity of the addressable RCC market
for BLU-5937, the ability to expand and develop its project
pipeline, the ability to obtain adequate financing, the ability of
BELLUS Health to maintain its rights to intellectual property and
obtain adequate protection of future products through such
intellectual property, the impact of general economic conditions,
general conditions in the pharmaceutical industry, the impact of
the COVID-19 pandemic on BELLUS Health’s operations, plans and
prospects, including to the initiation and completion of clinical
trials in a timely manner or at all, changes in the regulatory
environment in the jurisdictions in which BELLUS Health does
business, stock market volatility, fluctuations in costs, changes
to the competitive environment due to consolidation, achievement of
forecasted burn rate, potential payments/outcomes in relation to
indemnity agreements and contingent value rights , achievement of
forecasted preclinical study and clinical trial milestones,
reliance on third parties to conduct preclinical studies and
clinical trials for BLU-5937 and that actual results may vary once
the final and quality-controlled verification of data and analyses
has been completed. In addition, the length of BELLUS Health’s
product candidate’s development process and its market size and
commercial value are dependent upon a number of factors. Moreover,
BELLUS Health’s growth and future prospects are mainly dependent on
the successful development, patient tolerability, regulatory
approval, commercialization and market acceptance of its product
candidate BLU-5937 and other products. Consequently, actual future
results and events may differ materially from the anticipated
results and events expressed in the forward-looking statements.
BELLUS Health believes that expectations represented by
forward-looking statements are reasonable, yet there can be no
assurance that such expectations will prove to be correct. The
reader should not place undue reliance, if any, on any
forward-looking statements included in this news release. These
forward-looking statements speak only as of the date made, and
BELLUS Health is under no obligation and disavows any intention to
update publicly or revise such statements as a result of any new
information, future event, circumstances or otherwise, unless
required by applicable legislation or regulation. Please see BELLUS
Health's public filings with the Canadian securities regulatory
authorities, including, but not limited to, its Annual Information
Form, and the United States Securities and Exchange Commission,
including, but not limited to, its Annual Report on Form 40-F, for
further risk factors that might affect BELLUS Health and its
business.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210510005094/en/
Danny Matthews Director, Investor Relations and Communications
danny@bellushealth.com
Media: Julia Deutsch Solebury Trout
jdeutsch@soleburytrout.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Mar 2024 to Apr 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Apr 2023 to Apr 2024